NEALS will be holding its first annual Virtual ALS Clinical Research Learning Institute (CRLI) this month, January 2015, that will discuss amyotrophic lateral sclerosis (ALS). The ALS CRLI will be sponsored by the ALS Association’s TREAT ALS initiative. The ALS Clinical Research Learning Institute is an intensive program whose goal is to educate…
A new study on amyotrophic lateral sclerosis (ALS), entitled, “ATXN2 polyQ intermediate repeats are a modifier of ALS survival” published in Neurology by Dr. A. Chiò from the ALS Center, Department of Neuroscience, University of Torino in Italy, evaluated the rate of…
A $30 million alliance between Biogen Idec and Columbia University Medical Center was formed to conduct research in genetics and to understand the underlying causes of several diseases such as amyotrophic lateral sclerosis (ALS). This new partnership may help identify new treatment approaches to address the largely unmet clinical needs…
A group of researchers from the King’s College London recently published a new editorial entitled, “Heritability of Amyotrophic Lateral Sclerosis” in the journal JAMA Neurology – the official journal of the American Medical Association, that comments on the heritability estimation results of amyotrophic lateral sclerosis from a previous…
The U.S. Patent and Trademark Office (USPTO) recently granted clinical stage biopharmaceutical company and subsidiary of Allied Minds, SciFluor Life Sciences, LLC, a patent for one of their novel pipeline compounds, SF0034, a potent and selective neuronal potassium channel activator that is being studied for the treatment of epilepsy, amyotrophic lateral sclerosis…
BrainStorm Cell Therapeutics, Inc., a biotechnology company focused on developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), recently announced the latest Phase 2a clinical trial results of NurOwn™, a technology that differentiates bone marrow-derived mesenchymal…
Recent evidence shows that in amyotrophic lateral sclerosis (ALS), there occurs a notable deposition of abnormal ubiquitinated inclusions immunoreactive to TDP-43. In order to provide an early diagnosis and to conduct clinical trials for early treatment for ALS, it is crucial to fully understand muscle pathology in this condition. The study, entitled,…
A recent review, entitled, “Patient-Perceived Outcomes and Quality of Life in ALS”, which was published in the journal Neurotherapeutics last December 11, 2014, examined current evidence concerning the Quality of Life assessment measures for patients with amyotrophic lateral sclerosis (ALS). The…
In trying to determine the basis for volumetric changes seen in patients with amyotrophic lateral sclerosis (ALS), Drs. Venkateswaran Rajagopalan and Erik Pioro of the Cleveland Clinic have used voxel based morphometry to measure motor and extramotor grey matter volumes. The two recently delved into a study,…
The accumulation of specific metals may trigger neuronal degeneration associated with Amyotrophic lateral sclerosis (ALS), according to a study conducted on residents of the Kii Peninsula in Japan. The study, titled, “Neutron Activation Analysis of Scalp Hair from ALS Patients and Residents in the Kii Peninsula, Japan” was…
Get regular updates to your inbox.
